Breaking News
April 26, 2019 - Can Obesity Shrink Your Brain?
April 26, 2019 - This oral appliance could help you (and your partner) sleep better
April 26, 2019 - Myelination deficits cause abnormal hypersocial behavior associated with Williams syndrome
April 26, 2019 - New sepsis detector uses photonics to make accurate diagnosis in less than thirty minutes
April 26, 2019 - New study describes process to diagnose rare genetic diseases in record time
April 26, 2019 - Scientists and patients gather in Vancouver to discuss about Stevens-Johnson syndrome
April 26, 2019 - Advance in breakthrough cancer treatment eliminates serious side effects
April 26, 2019 - Discovery about cold sensing could pave way for new pain relief drugs
April 26, 2019 - Children often turn to sugary drinks instead of water
April 26, 2019 - Genome analysis shows the combined effect of many genes on cognitive traits
April 26, 2019 - Patients Caught In Middle Of Fight Between Health Care Behemoths
April 26, 2019 - Drug overdoses among adolescents and young adults on the rise
April 26, 2019 - Implementing a Paperless QC Micro Laboratory”
April 25, 2019 - Obesity linked to a reduction in gray matter
April 25, 2019 - Smart assistants could help combat opioid crisis
April 25, 2019 - Diagnostic stewardship strategy reduces inappropriate testing
April 25, 2019 - Three-antibiotic cocktail eradicates ‘persister’ Lyme bacteria in mouse model
April 25, 2019 - Study investigates how early blindness shapes sound processing
April 25, 2019 - Outcomes Worse for Cancer Patients Seen at Noncancer EDs
April 25, 2019 - Link found between temperament of high-risk infants and obesity
April 25, 2019 - Al Letson explores ties between journalists and doctors at Medicine and the Muse symposium
April 25, 2019 - New mobile phone game can detect people at risk of Alzheimer’s
April 25, 2019 - Scientists discover trigger region for absence epileptic seizures
April 25, 2019 - Stretchy wearable patch can do a health check while you work out
April 25, 2019 - Exercise activates brain circuits associated with memory in older adults
April 25, 2019 - Veggies, Fruits and Grains Keep Your Heart Pumping
April 25, 2019 - Healthy meal kits can boost children’s long-term health
April 25, 2019 - Designing an inexpensive surgical headlight: A Q&A with a Stanford surgeon
April 25, 2019 - States Weigh Banning A Widely Used Pesticide Even Though EPA Won’t
April 25, 2019 - Integrator complex proteins are crucial for healthy brain development in fruit flies, study finds
April 25, 2019 - Device converts brain signals into speech, offering hope for patients
April 25, 2019 - Measles vaccination rates are a ‘public health time bomb’
April 25, 2019 - Maths made easier for scientists students who shun the subject wins award
April 25, 2019 - Researchers decode how cancer drug works in brains of Parkinson’s disease patients
April 25, 2019 - Smarter Brain Cancer Trial Comes to Columbia
April 25, 2019 - Researchers Seek Sage Advice Of Elders On Aging Issues
April 25, 2019 - New chemical synthesis strategy leads to identification of novel, simpler derivatives
April 25, 2019 - Vanderbilt investigators discover link between vascular biology and eye disease
April 25, 2019 - Feces transplantation is effective and provides economic benefits
April 25, 2019 - Eisenhower Health first in Southern California to offer new lung valve treatment for COPD/emphysema
April 25, 2019 - Johns Hopkins researchers uncover role of neurotransmitter in the spread of aggressive cancers
April 25, 2019 - Porvair Sciences offers highly effective P3 microplate for biological sample clean-up
April 25, 2019 - Air pollution increases risk for respiratory hospitalization among childhood cancer survivors
April 25, 2019 - We are sitting more! How bad is that?
April 25, 2019 - Majority of stroke survivors not screened for osteoporosis, despite increased risk
April 25, 2019 - ADHD Screening: MedlinePlus Lab Test Information
April 25, 2019 - Cellular alterations increase vulnerability of obese and diabetic individuals to infection
April 25, 2019 - Association Insurance Pushes On Despite Court Ruling
April 25, 2019 - Traditional and e-cigarette users may be more receptive to smoking cessation interventions
April 25, 2019 - Delving into tumor’s cellular lineage may offer clues for customized therapies
April 25, 2019 - Two studies uncover brain mechanisms underlying decision making process
April 25, 2019 - Cardiometabolic Risk Better ID’d in Children Reclassified to Higher BP
April 25, 2019 - How the obesity epidemic is taking a toll on our bones and joints
April 25, 2019 - E-cigarettes contaminated with dangerous microbial toxins
April 25, 2019 - Researchers document specific characteristics of storefront tobacco advertisements
April 25, 2019 - Oncotype DX-guided treatment could reduce cost for breast cancer care, study suggests
April 25, 2019 - Predicting whether a patient will benefit from chemotherapy
April 25, 2019 - New review highlights how lifestyle affects our genes
April 25, 2019 - Study provides evidence that blood tests can detect Alzheimer’s risk
April 25, 2019 - Computer program mimics natural speech using brain signals from epilepsy patients
April 25, 2019 - Physicians turning to antibiotic alternatives for long-term acne treatment
April 25, 2019 - Preschool Is Prime Time to Teach Healthy Lifestyle Habits
April 25, 2019 - Study finds insidious and persistent discrimination among physician mothers
April 25, 2019 - Newly identified skin-gut communication helps illuminate link between food allergy and eczema
April 25, 2019 - Thiazide use linked with reduced risk of low energy fractures in people with Alzheimer’s
April 25, 2019 - Some women are biologically more resilient than others to PTSD
April 25, 2019 - The Current issue of “The view from here” is concerned with Partnerships and Alliances
April 25, 2019 - Imaging method reveals long-lived patterns in cells of the eye
April 25, 2019 - Podcast: KHN’s ‘What The Health?’ The Abortion Wars Rage On
April 25, 2019 - Prolonged exposure therapy is more effective in treating veterans with PTSD, alcohol use disorder
April 24, 2019 - Our artificial cornea breakthrough could lead to self-assembling organs
April 24, 2019 - A Stanford black, female, gay surgery resident speaks out
April 24, 2019 - Donna Lynne on Extreme Sports, Lessons From the '60s, and Taking CUIMC to the Next Level
April 24, 2019 - Pain Clinics’ Doctors Needlessly Tested Hundreds Of Urine Samples, Court Records Show
April 24, 2019 - Researchers uncover potential clue to halt destruction of nerve cells in people with ALS
April 24, 2019 - Study uncovers reasons for poor mental health in bisexual people
April 24, 2019 - Screenings, interventions, and referrals can help adolescents overcome substance abuse
April 24, 2019 - Febrile seizures following vaccination are self-resolving and not dangerous
April 24, 2019 - Flow-UV inline UV-Visible spectrometer monitors dispersion in real time
April 24, 2019 - Rates of Marijuana Use in Cancer Patients on the Rise in U.S.
Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial

Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial

image_pdfDownload PDFimage_print

INDIANAPOLIS, June 5, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today new safety and efficacy data from a Phase 2 study evaluating mirikizumab in patients with moderate-to-severe ulcerative colitis (UC). The results showed that patients treated with mirikizumab achieved significantly greater rates of clinical remission at 12 weeks compared to placebo. Detailed results from the Phase 2 trial will be presented today in a late-breaking abstract session at Digestive Disease Week (DDW) in Washington, D.C.

“We are proud to present these Phase 2 results for mirikizumab at DDW, which represent the first public disclosure of data on the safety and efficacy of an IL-23p19 monoclonal antibody in patients with moderate-to-severe UC,” said Lotus Mallbris, M.D., vice president, immunology platform team leader, Lilly Bio-Medicines. “These positive data affirm our confidence in the potential for mirikizumab to be an option for people living with immune-mediated diseases looking for a treatment that addresses their life-altering symptoms. We look forward to advancing our Phase 3 clinical development program for mirikizumab in UC, in addition to continuing our ongoing Phase 3 trial for mirikizumab in moderate-to-severe plaque psoriasis.”

The Phase 2 study evaluated the safety and efficacy of mirikizumab compared to placebo in patients with moderate-to-severe UC who had previously failed conventional or biologic therapy. In the study, patients were randomized to receive either mirikizumab (50 mg or 200 mg with the possibility of exposure-based increases up to 600 mg, or 600 mg fixed dose) or placebo. The primary and secondary endpoints at 12 weeks were the percentages of patients treated with mirikizumab achieving clinical remission, clinical response, endoscopic healing, endoscopic remission and symptomatic remission.

At 12 weeks, patients achieved the following response rates:

  • Clinical remission: Across all doses studied, between 11.5 percent to 22.6 percent of patients treated with mirikizumab achieved clinical remission, compared to 4.8 percent of those treated with placebo (nominal p-value
  • Clinical response: Across all doses studied, between 41.3 percent to 59.7 percent of patients treated with mirikizumab achieved clinical response, compared to 20.6 percent of those treated with placebo (nominal p-value
  • Endoscopic healing: Across all doses studied, between 13.1 percent to 30.6 percent of patients treated with mirikizumab achieved endoscopic healing, compared to 6.3 percent of those treated with placebo (nominal p-value

Additionally, greater proportions of patients treated with mirikizumab achieved endoscopic remission and symptomatic remission compared to placebo at 12 weeks. The proportion of patients achieving endoscopic remission was not statistically significant.

The incidence of serious adverse events and treatment-emergent adverse events (TEAEs) was similar across treatment groups. Among the most common TEAEs reported across all treatment groups, rates of nasopharyngitis, anemia and headache were similar between mirikizumab and placebo groups; a greater proportion of patients reported worsening of ulcerative colitis in the placebo group compared to patients in the mirikizumab groups.

“I am particularly encouraged by the symptomatic response and remission data we’ve seen thus far, and look forward to having data from later periods in the study to provide insight about the degree to which endoscopy results continue to improve over time, as we’ve observed in other clinical programs for UC,” said William J. Sandborn, M.D., Chief, Division of Gastroenterology, Professor of Medicine at the University of California San Diego School of Medicine. “Data from this Phase 2 trial indicate that if approved, mirikizumab may be an effective treatment option for patients with moderate-to-severe UC.”

About Mirikizumab

Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for the treatment of immune diseases, including psoriasis, ulcerative colitis and Crohn’s disease.

About Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the colon.1 UC occurs when the immune system sends white blood cells into the lining of the intestines, where they produce chronic inflammation and ulcerations.1 UC affects millions of patients globally.2 Early and sustained symptom relief, improvement in the appearance of the mucosa, and clinical remission are important treatment goals for healthcare providers and patients.2 There is an unmet need for treatment options for UC that provide meaningful symptom relief and deliver sustained clinical remission.

About the Mirikizumab Phase 2 Trial in UC

The Phase 2, multi-center, randomized, double-blind, placebo-controlled trial was designed to evaluate the safety and efficacy of mirikizumab in patients with moderate-to-severe UC. The primary endpoint in the study was the percentage of patients achieving clinical remission at 12 weeks, as defined by a Mayo rectal bleeding subscore of 0; a stool frequency subscore of 0 or 1, plus a decrease ≥1 from baseline; and an endoscopy subscore of 0 or 1. The study also evaluated secondary endpoints, including clinical response, as defined by a Mayo subscore decrease of ≥2 points and a ≥35 percent change in from induction baseline, excluding PGA; endoscopic healing, as defined by a Mayo endoscopy subscore of 0 or 1; endoscopic remission, as defined by a Mayo endoscopy subscore of 0; and symptomatic remission, as defined by a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0. For additional information on this trial, please visit clinicaltrials.gov.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about mirikizumab as a potential treatment for patients with ulcerative colitis, psoriasis and Crohn’s disease, and reflects Lilly’s current belief. As with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date, that mirikizumab will receive regulatory approvals, or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

1 What is Ulcerative Colitis? Crohn’s and Colitis Foundation Website. http://www.crohnscolitisfoundation.org/what-are-crohns-and-colitis/what-is-ulcerative-colitis/. Accessed June 5, 2018.
2 Adelphi Data 2017.

SOURCE Eli Lilly and Company

Posted: June 2018

About author

Related Articles